NEOG Stock Analysis: Neogen | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 2.033m USD | 12M Return: 72.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 16.4M
EPS Trend: -76.7%
Qual. Beats: 1
Rev. Trend: -9.4%
Qual. Beats: 3
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Neogen Corporation is a global developer, manufacturer, and marketer of products and services for food and animal safety, organized into two reporting segments. The Food Safety segment offers diagnostic test kits, laboratory services, and software used to detect pathogens, toxins, allergens, drug and pesticide residues, and other contaminants in human food and animal feed. The Animal Safety segment supplies veterinary instruments, reagents, immunoassay components, genomics services, and animal care products used in livestock and companion animal markets.
Neogen operates a primarily business-to-business distribution model, selling to food producers and processors, veterinarians, livestock producers, breeding companies, diagnostic laboratories, universities, retailers, and government agencies in the United States and internationally. Products reach end users through direct sales and distributor networks across multiple verticals including milling, meat and poultry, dairy, beverage, and dietary supplements.
Founded in 1981 and headquartered in Lansing, Michigan, Neogen trades on the NASDAQ under the ticker NEOG. It is classified within the Health Care sector under the GICS framework, a categorization that reflects the diagnostic testing orientation of much of its product portfolio.
- Food Safety segment grows on pathogen and allergen testing demand
- Animal Safety genomics services expand livestock revenue base
- 3M merger debt servicing pressures margins and capital allocation flexibility
| Net Income: -608.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA 2.34 > 1.0 |
| NWC/Revenue: 50.47% < 20% (prev 45.31%; Δ 5.16% < -1%) |
| CFO/TA 0.02 > 3% & CFO 69.5m > Net Income -608.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.92 > 1.5 & < 3 |
| Outstanding Shares: last quarter (217.7m) vs 12m ago 0.31% < -2% |
| Gross Margin: 42.56% > 18% (prev 41.57%; Δ 0.99% > 0.5%) |
| Asset Turnover: 23.54% > 50% (prev 22.45%; Δ 1.10% > 0%) |
| Interest Coverage Ratio: -9.08 > 6 (EBIT TTM -565.7m / Interest Expense TTM 62.3m) |
| A: 0.13 (Total Current Assets 590.0m - Total Current Liabilities 150.6m) / Total Assets 3.36b |
| B: -0.16 (Retained Earnings -533.0m / Total Assets 3.36b) |
| C: -0.15 (EBIT TTM -565.7m / Avg Total Assets 3.70b) |
| D: 1.67 (Book Value of Equity 2.10b / Total Liabilities 1.26b) |
| Altman-Z'' = 1.07 = BB |
| DSRI: 0.89 (Receivables 137.1m/160.1m, Revenue 870.5m/906.0m) |
| GMI: 0.98 (GM 41.57% / 42.56%) |
| AQI: 0.93 (AQ_t 0.72 / AQ_t-1 0.78) |
| SGI: 0.96 (Revenue 870.5m / 906.0m) |
| TATA: -0.20 (NI -608.8m - CFO 69.5m) / TA 3.36b) |
| Beneish M = -3.23 (Cap -4..+1) = AA |
As of July 11, 2026, the stock is trading at USD 9.62 with a total of 1,526,970 shares traded. Over the past week, the price has changed by +3.00%, over one month by +4.91%, over three months by +2.12% and over the past year by +72.40%.
Current recommended Stop Loss: 8.50 (which is 11.6% or 2.7 ATR below the current price).
Neogen has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy NEOG.
- StrongBuy: 2
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 12 | 24.7% |
P/E Forward = 16.0
P/S = 2.3354
P/B = 0.9644
P/EG = 0.6575
Revenue TTM = 870.5m USD
EBIT TTM = -565.7m USD
EBITDA TTM = -448.6m USD
Long Term Debt = 793.3m USD (from longTermDebt, last quarter)
Short Term Debt = 27.4m USD (from shortTermDebt, last fiscal year)
Debt = 795.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 2.45m
Net Debt = 635.8m USD (calculated: Debt 795.7m - CCE 159.9m)
Enterprise Value = 2.67b USD (2.03b + Debt 795.7m - CCE 159.9m)
Interest Coverage Ratio = -9.08 (Ebit TTM -565.7m / Interest Expense TTM 62.3m)
EV/FCF = 63.88x (Enterprise Value 2.67b / FCF TTM 41.8m)
FCF Yield = 1.57% (FCF TTM 41.8m / Enterprise Value 2.67b)
FCF Margin = 4.80% (FCF TTM 41.8m / Revenue TTM 870.5m)
Net Margin = -69.93% (Net Income TTM -608.8m / Revenue TTM 870.5m)
Gross Margin = 42.56% ((Revenue TTM 870.5m - Cost of Revenue TTM 500.0m) / Revenue TTM)
Gross Margin QoQ = 46.88% (prev 47.48%)
Tobins Q-Ratio = 0.79 (Enterprise Value 2.67b / Total Assets 3.36b)
Interest Expense / Debt = 7.83% (Interest Expense 62.3m / Debt 795.7m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -446.9m (EBIT -565.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.92 (Total Current Assets 590.0m / Total Current Liabilities 150.6m)
Debt / Equity = 0.38 (Debt 795.7m / totalStockholderEquity, last quarter 2.10b)
Debt / EBITDA = -1.42 (negative EBITDA) (Net Debt 635.8m / EBITDA -448.6m)
Debt / FCF = 15.22 (Net Debt 635.8m / FCF TTM 41.8m)
Total Stockholder Equity = 2.10b (last 4 quarters mean from totalStockholderEquity)
RoA = -16.46% (Net Income -608.8m / Total Assets 3.36b)
RoE = -29.00% (Net Income TTM -608.8m / Total Stockholder Equity 2.10b)
RoCE = -19.56% (EBIT -565.7m / Capital Employed (Equity 2.10b + L.T.Debt 793.3m))
RoIC = -14.00% (negative operating profit) (NOPAT -446.9m / Invested Capital 3.19b)
WACC = 9.48% (E(2.03b)/V(2.83b) * Re(10.77%) + D(795.7m)/V(2.83b) * Rd(7.83%) * (1-Tc(0.21)))
Discount Rate = 10.77% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 98.88 | Cagr: 0.26%
[DCF] Terminal Value 71.57% ; FCFF base≈41.8m ; Y1≈41.9m ; Y5≈44.4m
[DCF] Fair Price = N/A (negative equity: EV 579.6m - Net Debt 635.8m = -56.2m; debt exceeds intrinsic value)
EPS Correlation: -76.75 | EPS CAGR: -19.89% | SUE: 1.09 | # QB: 1
Revenue Correlation: -9.44 | Revenue CAGR: -0.36% | SUE: 1.03 | # QB: 3
EPS current Quarter (2026-08-31): EPS=0.05 | Chg30d=+11.11% | Revisions=-25% | Analysts=3
EPS current Year (2026-05-31): EPS=0.37 | Chg30d=+0.00% | Revisions=+17% | GrowthEPS=+12.1% | GrowthRev=-4.2%
EPS next Year (2027-05-31): EPS=0.30 | Chg30d=+1.11% | Revisions=-17% | GrowthEPS=-18.9% | GrowthRev=-1.0%
[Analyst] Revisions Ratio: -10% (up=3, down=4)